Reports Q2 revenue $603.83M , consensus $555.68M.David Epstein, Chief Executive Officer of Seagen said, “I am pleased to report an exceptional quarter with strong performance and growth seen across our commercial portfolio. We remain focused on optimizing the potential of our commercial portfolio, advancing our innovative pipeline of targeted therapies with ADCs at our core and innovating through next-generation technologies.” Highlights include: PADCEV in combination with Keytruda, pembrolizumab, received accelerated approval for first-line treatment of locally advanced or metastatic urothelial cancer in the U.S. and was added as a preferred regimen to NCCN treatment guidelines. The robust launch helped drive 36% net product sales growth for PADCEV over the first quarter of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seattle Genetics put volume heavy and directionally bearish
- TD Cowen analysts to hold an analyst/industry conference call
- Seagen, Pfizer receive Second Request from FTC regarding merger
- Seagen, Pfizer to receive FTC second request, Dealreporter says
- Seagen reports progression free survival data from Adcetris combination study
